Overview

A Long Term, Safety Study of Apricitabine in HIV-infected Subjects

Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
The study will examine how safe and effective apricitabine is when given long term (as ongoing treatment) to HIV patients who have already completed the AVX-201 trial
Phase:
Phase 2
Details
Lead Sponsor:
Avexa